Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Retained Earnings (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Retained Earnings for 12 consecutive years, with -$222580.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 8.66% to -$222580.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$222580.0, a 8.66% decrease, with the full-year FY2025 number at -$21.7 million, down 6.24% from a year prior.
  • Retained Earnings was -$222580.0 for Q4 2025 at Regen BioPharma, up from -$21.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$204847.0 in Q4 2024 to a low of -$87.8 million in Q1 2022.
  • A 5-year average of -$19.6 million and a median of -$20.2 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 506.46% in 2022, then soared 98.99% in 2025.
  • Regen BioPharma's Retained Earnings stood at -$20.7 million in 2021, then grew by 6.93% to -$19.3 million in 2022, then dropped by 4.3% to -$20.1 million in 2023, then soared by 98.98% to -$204847.0 in 2024, then fell by 8.66% to -$222580.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Retained Earnings are -$222580.0 (Q4 2025), -$21.7 million (Q3 2025), and -$204847.0 (Q2 2025).